Merckâ€™s earnings call disclosed lowered short-term and long-term financial guidance due to manufacturing delays affecting vaccine supply, challenges with key products like Singulair, Gardasil, and the cholesterol franchise, as well as unfavorable currency impacts. The announcement of significant job cuts and restructuring highlights operational difficulties. These negative factors are expected to weigh on investor sentiment and lead to a decline in the stock price in the short term.
[-2]